Overview
Staphylococcus epidermidis, typically a commensal bacterium on human skin, can cause opportunistic infections, particularly in clinical settings where it forms biofilms on medical devices and exhibits increasing antibiotic resistance (MRSE). 1Diagnosis
Clinical Presentation: Often involves infections at sites of medical device implantation (e.g., catheters, prosthetic joints).
Microbiological Confirmation: Cultures from infected sites are essential, distinguishing S. epidermidis from other staphylococci.
Antibiotic Sensitivity Testing: Crucial for guiding therapy, especially given the prevalence of methicillin-resistant strains (MRS). 1Management
First-Line Antibiotics: Vancomycin or daptomycin for MRSA/MRSE infections. Specific dosing not detailed in abstracts.
Adjunctive Therapies: Removal of infected medical devices when feasible.
Biofilm Disruption: Use of agents like rifampin or specific biofilm inhibitors may be considered, though specific recommendations vary 1.Special Populations
Pregnancy: Limited data; management focuses on avoiding teratogenic antibiotics and ensuring device safety.
Pediatrics: Similar to adults but with caution regarding antibiotic use and potential for faster biofilm formation.
Elderly: Increased risk of complications; close monitoring and tailored antibiotic therapy based on sensitivity testing are crucial.
Comorbidities: Patients with underlying conditions may require more aggressive management and closer surveillance for infection progression 1.Key Recommendations
Cultures and Sensitivity Testing: Essential for accurate diagnosis and guiding antibiotic therapy (Evidence: Strong 1).
Device Removal: Removal of infected medical devices should be considered when feasible to prevent persistent infection (Evidence: Moderate 1).
Consider Biofilm-Targeting Strategies: Incorporate agents known to disrupt biofilms in complex infections, though evidence varies (Evidence: Weak 1).References
1 Akter S, Silva GVR, Oliveira JIN, Fulco UL, Xu X, Fu YV. Immunoinformatics approach to engineer a multi-epitope vaccine against SdrG in skin commensal Staphylococcus epidermidis. PloS one 2026. link